REGULATORY

• MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
  April 21, 2014

• DPJ Member Nagatsuma Asks MHLW to Consider Criminal Complaint over SIGN Trial
  April 18, 2014

• New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
  April 18, 2014

• Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
  April 18, 2014

• Govt Deregulation Panel Tenders Prerequisites for Envisaged Mixed Care System
  April 17, 2014

• MHLW to Mull Applying Mixed Care Scheme to Low Cost-Effective Drugs: Minister
  April 17, 2014

• Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
  April 17, 2014

• PAFSC’s First Committee to Review Canagliflozin, Japan’s 5th SGLT-2 Inhibitor
  April 15, 2014

• Pharma Leaders Push Abe Govt to Permanently Introduce Key Premium, R&D Tax Credit
  April 15, 2014

• MHLW Panel on Counterfeit Drugs Holds First Meeting
  April 14, 2014

• MHLW Diovan Panel Finalizes Report following Fine-Tuning
  April 14, 2014

• “Transparency Must Be Ensured” for Funding by Pharmas: Minister
  April 14, 2014

• Number of High-Cost New Drugs to Be Reimbursed Under Fee-for-Service System: Chuikyo
  April 14, 2014

• Japan NIH Will Have Research Topic-Based Units to Stem Sectionalism: Official
  April 11, 2014

• Japanese NIH-Related Bills Clear Lower House
  April 11, 2014

• 14-Day Prescription Limit to Be Ruled Out for Anti-HIV Drug Tivicay
  April 11, 2014

• Official Says Health Ministry Will Notify Industry about Electronic Data Submissions around June
  April 11, 2014

• Abe’s Govt, Pharma Leaders to Hold Public-Private Dialogue on April 14
  April 10, 2014

• MHLW Says Additional Data Needed for OBLEAN Listing
  April 10, 2014

• Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
  April 10, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 329
• 330
• 331
• 332
• 333
• 334
• 335
• 336
• 337
• …
• Next ›
• 最終 »